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Abstract
The recombinant circumsporozoite protein (CS) based vaccine, RTS,S, confers protection against Plasmodium falciparum
infection in controlled challenge trials and in field studies. The RTS,S recombinant antigen has been formulated with two
adjuvant systems, AS01 and AS02, which have both been shown to induce strong specific antibody responses and CD4 T
cell responses in adults. As infants and young children are particularly susceptible to malaria infection and constitute the
main target population for a malaria vaccine, we have evaluated the induction of adaptive immune responses in young
children living in malaria endemic regions following vaccination with RTS,S/AS01E and RTS,S/AS02D. Our data show that a
CS-specific memory B cell response is induced one month after the second and third vaccine dose and that CS-specific
antibodies and memory B cells persist up to 12 months after the last vaccine injection. Both formulations also induced low
but significant amounts of CS-specific IL-2
+ CD4
+ T cells one month after the second and third vaccine dose, upon short-
term in vitro stimulation of whole blood cells with peptides covering the entire CS derived sequence in RTS,S. These results
provide evidence that both RTS,S/AS01E and RTS,S/AS02D induced adaptive immune responses including antibodies,
circulating memory B cells and CD4
+ T cells directed against P. falciparum CS protein.
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Introduction
Vaccination against Plasmodium falciparum (P. falciparum) infection
and disease with an efficacious adjuvanted protein vaccine is an
efficient and feasible strategy to reduce the burden of malaria in
endemic regions. The candidate vaccine RTS,S targets the
circumsporozoite protein (CS) in the pre-erythrocytic stage of
the parasite and is based on a recombinant fusion protein (RTS)
comprising the CS central tandem repeats and the C-terminal
regions of CS fused to the N-terminal of hepatitis B surface antigen
[1]. Co-expression of this fusion protein with native HepB surface
antigen (S) results in the spontaneous formation of RTS,S virus-
like particles. When formulated with the AS02 adjuvant, RTS,S
was capable of inducing strong adaptive immune responses and
protection against parasite challenge [2,3]. The AS02 adjuvant is
composed of an oil-in-water emulsion, the TLR4 ligand mono-
phosporyl lipid A (MPL) and the saponin QS21 [1]. A number of
clinical trials using the RTS,S/AS02 formulation have shown
significant protection from infection in controlled challenge [3–6],
or in field studies performed in adults and children living in
malaria endemic regions [7–9]. New vaccine formulations were
assessed for their ability to induce improved CS-specific immune
responses. A second adjuvant named AS01 (which includes
liposomes, MPL and QS21) was selected on the basis of its ability
to induce comparable CS-specific antibody responses and greater
T cell responses in small animal models and non human primates
compared to the AS02 formulation [10,11]. This was confirmed in
a phase IIa controlled challenge study performed in healthy
malaria naı ¨ve adults, where the RTS,S/AS01 formulation was
shown to be safe and well tolerated, to induce strong humoral and
cellular immune responses and to provide an improved protection
against P. falciparum challenge as compared to RTS,S/AS02 [3].
+
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with AS01 or AS02 is safe and highly immunogenic in adults [12]
as well as in young children living in malaria endemic regions, and
can reduce both infection rates and disease severity [13].
Both antibodies and T cell pre-erythrocytic responses have been
shown to confer protection against Plasmodium infection in small
animal studies [14–21]. The immune mechanisms underlying
protection in humans have not been formally identified but recent
evidence suggests that anti-CS mediated protection in adults
depends on both strong antibodies and CD4
+ T cell responses [3].
Since pediatric populations in endemic areas constitute the main
target group for a malaria vaccine, it is important to investigate
immune responses induced by RTS,S vaccines in this age group
and also provide a better understanding of immune mechanisms
which mediate protection. In this study we have investigated the
impact of RTS,S vaccination on the induction of CS-specific
antibodies, circulating memory B cells and CD4
+ T cell responses
in children aged 18 months to 4 years, vaccinated with AS01E or
AS02D based formulations. While the rationale for investigating
CD4
+ T cell responses is based on their potential role in protection
against infection in adults [3,6], memory B cell responses and their
relation to circulating antibody titers have not been evaluated with
the RTS,S candidate vaccine.
Materials and Methods
The supporting CONSORT checklist for this trial is available as
supporting information; see Checklist S1. The protocol of this trial
was posted with a previous publication [22].
Ethics statement
The ethics committee of the International Foundation of the
Albert Schweitzer Hospital of Lambare ´ne ´ and the Western
Institutional Review Board (USA) approved the study protocol.
The trial was undertaken following the International Conference
on Harmonisation of Good Clinical Practice guidelines. GSK
Biologicals, Rixensart, Belgium, monitored the trial. In addition, a
local safety monitor and a data and safety monitoring board
closely reviewed the conduct and results of the trial.
Study design and sampling
This trial has been described in detail in a previous publication
[22]. It consisted of a phase II randomized, double blind study
designed to document safety, reactogenicity and immunogenicity
of the RTS,S/AS01E and RTS,S/AS02D formulations adminis-
tered intramuscularly at 0, 1 and 2 months in children aged 18
months to 4 years in Lambare ´ne ´, Gabon. The primary endpoint of
the trial was safety. The immunological analyses presented here
were exploratory endpoints. A total of 180 eligible children were
randomly assigned to a treatment group on the day of first
vaccination. Because of limited volumes of blood, each group was
randomly divided into two subgroups for evaluation of memory B
cell responses using Enzyme Linked Immunospot Assay (ELI-
SPOT) or T cell responses by detection of intracellular cytokine
expression using whole blood. Blood samples were collected in
lithium-heparin tubes before vaccination, one month post doses 2
and 3 and 12 month post dose 3 (study month 14). Peripheral
blood mononuclear cells (PBMCs) for use in the memory B cells
ELISPOT assay were isolated using Ficoll-Paque PLUS (GE
healthcare, Germany).
Detection of anti-CS and anti-HBs antibodies
Blood samples were collected before vaccination, one month post
doses 2 and 3 and 12 months post dose 3. In all participants, serum
antibodies to the NANP repeat region of CS (B cell epitope) were
measured by a standard, validated enzyme-linked immunosorbent
assay (ELISA) using plates adsorbed with the recombinant antigen
R32LR that contains the sequence [NVDP(NANP)15]2LR, at a
GSK validated laboratory (CEVAC, University of Ghent, Belgium).
Titres were calculated using a reference standard curve with a 4
parameter logistic fitting algorithm and expressed in EU/ml, with
cut-off for seropositivity set at 0.5 EU/ml [23]. Anti-hepatitis B
surface antigen (HBs) antibody levels were measured with an in-
house developed ELISA described previously [24].
Detection of CS specific IgG secreting cells
The assay used for detection of circulating antigen specific B
cells is based on a published method [25]. Briefly, fresh human
PBMCs isolated by Ficoll density gradient were cultured at a
concentration of 10
6 cells/ml for 7 days in RPMI 1640 containing
1 mM sodium pyruvate, non-essential amino acids, 2 mM L-
glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 50 mM
2-mercapto-ethanol and 10% Fetal Calf serum in the presence of
2.5 mg/ml CpG 2006 (TIB – MOLBIOL, Germany) and 10 ng/
ml IL-15 (R&D Systems, Germany) at 37uC, 5% CO2 humidify
atmosphere in 24 well culture plates. Cultured cells were then
counted and transferred onto 96 well ELISA plates coated with
100 mlo f1 0mg/ml R32LR or with 5 mg/ml of c chain specific
goat anti-human IgG (Sigma, Germany) for 3 hours at 37uC and
saturated with PBS containing 3% BSA. CS-antigen specific
immune responses were measured in triplicates over a period of
three hours. A starting concentration of 10
6 cells/well followed by
two three-fold serial dilutions (333000, 111000 cells/well) was used
for non-coated and antigen-coated wells (if available, but less in
case of lower cell numbers extracted from the pediatric samples).
For the IgG positive control, threefold serial dilutions were done
with 27,000 cells/well as the highest density, followed by a series of
three three-fold dilutions (9000, 3000, 1000 cells/well). Plates were
washed and incubated with a biotin-labeled goat anti-human IgG
(Sigma, Germany) followed by streptavidin-alkaline phosphatase
(Roche, Germany). After a final washing step, wells were covered
with a 0.6% agarose solution in 1 M 2-amino-2-methyl-1-
propanol, 1.58 mM MgCl2, 0.01% Triton X-405 and 2.3 mM
5-Bromo-4-chloro-3-indolyl phosphate p-toluidine, pH 10.25.
Plates were then incubated for 3 hours at 37uC for spot
development, digitally photographed and counted manually using
ImageJ software (National Institutes of Health, USA). The
frequency of B lymphocytes expressing R32LR specific IgG was
expressed as a number of antigen-specific cells per total IgG
expressing cells after substraction of background responses.
Samples which had less than 2000 IgG
+ spots per million PBMCs
were not considered for analysis.
Whole blood Intracellular cytokine staining and flow
cytometry
Intracellular cytokine staining (ICS) was used to assess cell-
mediated immune responses, using a previously described method
[26]. Just after collection, samples of 350 ml undiluted whole blood
were incubated at 37uC with a pool of overlapping 15-mer
peptides spanning the CS sequence in RTS,S (1.25 mg/ml per
peptide), medium (negative control) or staphylococcal enterotoxin
B (SEB, 0.25 mg/ml, positive control) for 2 hours in the presence
of 1 mg/ml of anti-CD28 and anti-CD49d antibodies. Then,
cytokine secretion inhibitor (Brefeldin A) was added at 1 mg/ml
and incubated overnight. Following this, red blood cells were lysed
and white blood cells were washed, fixed, and cryopreserved, and
stored for cytometric analysis. Later, cells were thawed in bath,
washed and permeabilised. The cells were then incubated with
Immunogenicity of RTS,S/AS01E and RTS,S/AS02D
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CD40L, IFN-c, IL-2 and TNF-a (BD biosciences ). After washing,
flow cytometric acquisition was performed on a BD
TM LSR II
flow cytometer (BD biosciences, CA, USA), and analysis were
completed with BD
TM Diva software (BD biosciences, CA, USA)
or FlowJo software (Tree Star
TM Inc). Results are reported as the
frequency of CD4
+ and CD8
+ T cells expressing at least CD40L,
IFN- c, IL-2 or TNF-a. A child was considered to be a responder
if, upon CS antigen whole blood stimulation, the frequency of CS-
specific cytokine expressing T cells was greater than or equal to the
geometric mean + 3 standard deviations of cytokine expressing T
cells in unstimulated samples.
Statistical analysis
Immunogenicity analyses presented here were performed on the
According To Protocol cohort for immunogenicity which included
all subjects that received 3 doses of study vaccine according to
protocol and for whom valid immunogenicity measurements were
available.
The frequency of CS-specific B cells and T cells were
summarized by descriptive statistics and tabulated by study group
and timepoint. Between groups comparisons were performed by
Wilcoxon Rank Sum tests (ie Mann-Whitney-U test, 2 sided, alpha
0.05). Within group comparisons were performed by Wilcoxon
Signed Ranks test.
Spearman’s rank correlation co-efficient (R) was used to assess
the correlation between the log of anti-CS IgG level and log of the
frequency of circulating memory B cells.
No adjustment for multiplicity of analysis was done.
Results
Figure 1 shows the flow of subjects through the study.
RTS,S vaccines induce circulating memory B cells
producing CS-specific IgG
Vaccination with RTS,S has been shown to induce persistent
antibody responses to CS in malaria exposed Gambian adults [27]
and children in Mozambique [23]. The antibody responses to CS
and HBs in children vaccinated with RTS,S/AS01E and RTS,S/
AS02D in this study have been reported previously [22]. For
information, all subjects from the B cell memory subset were anti-
CS seropositive after the second vaccination with both vaccine
formulations. In this group of children, the geometric mean anti-
CS antibody concentration peaked after the third immunization
for RTS,S/AS01E and RTS,S/AS02D (GMT 196 EU/ml 95%
CI: 144–265 and 174 EU/ml 95% CI: 130–233 respectively) and
all subjects remained seropositive for anti-CS antibodies one year
after the last vaccine administration (GMT 15 EU/ml 95% CI:
10–24 and 19 EU/ml 95% CI: 12–31 respectively at month 14 of
the study).
To investigate whether vaccination with RTS,S/AS01E and
RTS,S/AS02D induced a memory B cell response in children, the
presence of circulating memory B cells producing IgG specific for
the P. falciparum CS protein was evaluated in this study using in vitro
maturated memory B cells to detect antibody secreting cells by
ELISPOT. Anti-CS antibody secreting cells were detected only in
a few subjects, in low numbers, before the first vaccine
administration (Table 1). At one month after the second RTS,S
vaccination, memory B cells secreting anti-CS specific IgG were
detected in the majority of study participants. ELISPOT responses
to the CS antigen were significantly higher than pre-vaccination
values after the second and third immunization in RTS,S/AS01E
and RTS,S/AS02D vaccinated children. At one month post dose 2
the number of CS-specific circulating memory B cells was
significantly higher in the RTS,S/AS01E group compared to
RTS,S/AS02D group, but this difference was not seen at later
timepoints. One year after last vaccination (month 14), the
frequency of CS-specific circulating memory B cells had decreased
in both groups but was still significantly higher than pre-
vaccination values.
Influence of prior vaccination with hepatitis B vaccine on
the levels of circulating CS-specific memory B cells
induced by RTS,S/AS01E and RTS,S/AS02D
As, in this study, prior exposure to hepatitis B vaccination was
associated with higher levels of CS-specific antibodies [22], it was
investigated whether the hepatitis B vaccination status also had an
impact on circulating CS-specific memory B cell responses in
ELISPOT. Such an effect was not detected here: similar
frequencies of CS-specific circulating memory B cells induced by
RTS,S/AS01E and RTS,S/AS02D were observed in hepatitis B
vaccinated and unvaccinated children. For example, at month 3
(one month post dose 3), the median (Q1–Q3) number of CS-
specific memory B cells in children in the RTS,S/AS01E group
previously vaccinated (N=16) or not (N=10) with hepatitis B
vaccine was, respectively 1617 (594–3718) and 1496 (525–4657);
in children in the RTS,S/AS02D group hepatitis B vaccinated
(N=16) or not (N=16) was 1496 (525–4657) and 2071 (1075–
3163), respectively.
Assessment of the correlation between the frequency of
CS-specific circulating memory B cells and CS-specific
antibody titers
Correlations between antigen-specific antibody levels and
memory B cells have been reported in adults [28] and infants
[29] for some vaccines. The relationship between CS-specific
antibody responses and the frequency of circulating CS-specific
memory B cells was investigated in this study (Figure 2). Analysis
using Spearman’s test (R) was done on subjects who were positive
for CS-specific memory B cells. Statistically significant positive
correlations between the CS-specific antibody level of each subject
and the corresponding frequency of CS-specific circulating memory
B cells were found at study month 2 (one month post dose 2) in the
RTS,S/AS02D group only and at month 3 (one month post dose 3)
in both study groups, but not at study month 14.
RTS,S/AS01E and RTS,S/AS02D induce CS-specific CD4
+ T
cell responses
T cell responses to the CS antigen have been reported to be
associated with protection in P. falciparum controlled challenge
trials [3,6]. Cellular responses to the CS antigen were therefore
investigated in young children vaccinated with RTS,S formulated
in AS01E or AS02D before vaccination and one month after the
second and third vaccination. The detection of the intracellular
cytokine expression following overnight stimulation with SEB
(positive control), the CS peptide pool or medium (negative
control) was performed by flow cytometry. Gating strategy and
representative Scatterplots are presented in Figure 3.
Low frequencies of CS- specific CD4
+ T cells expressing IL-2
were detected upon in vitro stimulation of whole blood in children
vaccinated with RTS,S/AS01E or RTS,S/AS02D (Figure 4). In
both study groups, the frequency of CS-specific IL-2
+ CD4
+ T
cells was significantly higher at one month post dose 2 and one
month post dose 3 compared to pre-vaccination values. No
significant differences were detected between the CS-specific IL-2
+
CD4
+ T cell responses when comparing RTS,S/AS01E and
Immunogenicity of RTS,S/AS01E and RTS,S/AS02D
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18559Figure 1. Flow of participants through the study.
doi:10.1371/journal.pone.0018559.g001
Table 1. Induction of memory B cell responses following vaccination with RTS,S/AS01E and RTS,S/AS02D (ATP cohort for
immunogenicity - B cell subset).
RTS,S/AS01E RTS,S/AS02D
RTS,S/AS01E vs RTS,S/
AS02D comparison
N Median (Q1–Q3) N Median (Q1–Q3) p-value
Pre 17 0 (0–20) 23 0 (249–0) 0.12
Month 2 31 1692 (345–4997)*** 28 183 (0–1429)*** 0.013
Month 3 29 1330 (466–2857)*** 32 1795 (662–3204)*** 0.38
Month 14 25 27 (0–2451)* 27 829 (25–1637)*** 0.2
Footnote: Number of CS-specific spots per million total IgG-positive cells are presented.
*p,0.05.
***p,0.001, statistically significant differences against pre-vaccination values.
doi:10.1371/journal.pone.0018559.t001
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CD4
+ T cells expressing at least IFN-c, TNF-a or CD40L were
not significantly higher than baseline values (data not shown). No
CS-specific CD8
+ T cell responses were detected one month after
vaccination (data not shown). Considering the low level of
response seen at peak (one month post dose 3) for IL-2
+ CD4
+
T cells, ICS analysis at 12 months post dose 3 was not performed.
For information, in children who had T cell responses assessed, the
induction of anti-CS antibodies (data not shown) showed a similar
pattern to what has been described for children in the B cell subset.
Discussion
This study investigated the adaptive B and T cell immune
responses induced by the RTS,S antigen formulated with two
different adjuvant systems in 18 month to 4 year old children living
Figure 2. Association between CS-specific antibody responses and the frequency of CS-specific IgG
+ memory B cells. The relationship
between CS-specific antibody responses and the frequency of circulating CS-specific memory B cells was analysed at one month post dose 2 (month
2), one month post dose 3 (month 3) and one year post dose 3 (month 14). Data represent the CS-specific antibody level of each subject versus the
corresponding frequency of CS-specific circulating memory B-cells for RTS,S/AS01E and RTS,S AS02D vaccine formulations. Number of responding
subjects (n), Spearman correlation coefficient (R) and p-value are indicated.
doi:10.1371/journal.pone.0018559.g002
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was performed following overnight stimulation with SEB (positive control), the CS peptide pool or medium. (A) Cytokine production by CS-specific
CD4
+ T cells was determined by first dividing the CD3
+ T cells in the lymphocyte gate into CD4
+ or CD8
+ T cells. (B) CD3
+ CD4
+ CD8
2 T cells were
analyzed with respect to the production of IL-2 and TNF-a. The unstimulated sample shows background levels of cytokine production, while
stimulation with SEB shows strong production of IL-2 or TNF-a by CD4
+ T cells. When restimulated with the CS peptide pool, the production of IL-2 by
CD4
+ T cells and low production of TNF-a was detected. (C) CD3
+ CD4
+ CD8
2 T cells were analyzed for polyfunctional responses by simultaneous
detection of IL-2 and TNF-a. While stimulation with SEB induces CD4
+ T cells which produce the single cytokines and cells which produce both IL-2
and TNF-a, restimulation with the CS peptide pool induces mainly CD4
+ T cells producing IL-2 only and a small fraction of cells is producing both IL-2
and TNF-a. The numbers in the quadrant gates of the plots denominates each distinct population based on their cytokine production. Samples from
the same subject are shown, with responses at one month post dose 2. Results shown are representative of the range of responses seen with all
subjects studied.
doi:10.1371/journal.pone.0018559.g003
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significant amounts of P. falciparum CS-specific IgG
+ memory B
cells and IL-2
+ CD4
+ T cells detected upon short-term in vitro
restimulation, after vaccination of young children with AS01E and
AS02D based formulations of the RTS,S pre-erythrocytic vaccine
candidate. Previous work has shown that in infants receiving
RTS,S/AS02D, a significant IL-2 production was detected in the
supernatant of blood lymphocytes upon long-term in vitro
restimulation with a CS-derived peptide pool [30].
This study demonstrates the induction one month after doses 2
and 3 as well as persistence at month 12 after last immunization of
CS- specific circulating memory B cell and CS-specific antibodies
in RTS,S/AS01E and RTS,S/AS02D vaccinated children. Similar
to the association between the levels of antibodies to serogroup C
meningococcal polysaccharide and the levels of circulating
memory B cells in infants vaccinated with the MenC glycocon-
jugate vaccine [29], these data suggest the replenishment of the
plasma cell pool on a regular basis through differentiation of CS
specific memory B cells [31]. An alternative model proposes that
long lived plasma cells would be solely responsible for the
maintenance of serum antibodies titers [32–34]. However, the
short half-life (between 40 to 100 days) of long-lived plasma cells
described in several animal and human studies [35–37] make a
scenario in which long-lived plasma cells sustain antibody
production without continuous replenishment from memory B
cells unlikely.
After two vaccine administrations, a higher frequency of CS-
specific memory B cells was induced with the RTS,S/AS01E than
with RTS,S/AS02D. This may suggest a stronger priming and
induction of large size germinal centers by RTS,S/AS01E as we
showed also a trend towards higher anti-CS antibody titers in the
recipients of RTS,S/AS01E in the same trial [22]. Strong
stimulation of germinal centers by primary course vaccination
has been suggested as a relevant factor for the persistence of the
Ag-specific antibodies and Ag-specific memory B cells. This is
supported by a trend toward a sustainable protective level of
antibodies to serogroup C meningococcal polysaccharide in
children vaccinated with MenC vaccine one year after the the
primary course in the 2/3 of children that elicited memory B cells
after third vaccination [38]. The majority of study participants in
both the RTS,S/AS01E and RTS,S/AS02D groups had a
significant level of memory B cells after the second vaccine dose
and maintained a significant level of CS-specific antibodies one
year after the last vaccination. The higher frequency of CS-specific
memory B cells induced with the RTS,S/AS01E after the second
dose may be associated with the higher immunogenicity and
efficacy of this vaccine observed in studies conducted in animals
and naı ¨ve adults [3,10,11].
In contrast to antibody responses [22], an effect of prior
exposure to the hepatitis B vaccine on the memory B cell response
to the CS antigen was not detected here. This should be
interpreted with caution in view of the low numbers involved in
this analysis. Additional investigations on the mechanisms
underlying the observed influence of previous hepatitis B
vaccination on the CS antibody level may be needed to
discriminate whether previous hepatitis B vaccination affects short
CS antibodies producing plasma cells.
The rationale for investigating CD4
+ T cell responses in
children is based on the observation that CS-specific CD4
+ T cells
are associated with increased protection in adults [3,6]. When
Figure 4. Induction of CD4
+ T cell responses following vaccination with AS01 and AS02 based RTS,S formulations. Frequency of CD4
+
T cells expressing at least IL-2 were measured before vaccination, one month after the second vaccination (month 2), and one month (month 3) after
the third vaccination (month 14). ICS data are represented for RTS,S/AS01E and RTS,S AS02D vaccine formulations, indicating Q1, Median, Q3.
Significant differences against pre-values are indicated as *** p,0.001, ** p,0.01 and * p,0.05. Minimum and maximum frequencies of IL-2
+ CD4
+ T
cell responses, the number of evaluated subjects and the responder rates are indicated.
doi:10.1371/journal.pone.0018559.g004
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+ T cell responses to the CS antigen in
children vaccinated with RTS,S/AS01E or RTS,S/AS02D, using
a whole blood assay, IL-2 expression by CD4
+ T cells was the
only significant response detected. CD40L expression was not
observed. While the children in this study had detectable CS-
specific IL-2
+ CD4
+ T cells, these responses were lower than those
seen, using a PBMC based assay, in malaria naı ¨ve adults
vaccinated with RTS,S/AS01 or RTS,S/AS02 [3]. Reduced
expression of cytokines such as IFN-c and TNF-a have been
documented following vaccination of infants and are thought to be
related to the somewhat immature status of the immune system
[39–41]. Technical hurdles associated with CMI assessment in the
field cannot be ruled out. CS-specific CD8
+ T cells were not
detected at one month post dose 2 and 3, in agreement with the
absence of a detectable CD8
+ T cell response to vaccination with
RTS,S/AS01 or RTS,S/AS02 in adults [3].
Production of IL-2 has been linked to the establishment of
memory T cell responses. It has been suggested that IL-2 and IFN-
c producing T cells after vaccination of adults are associated with
the induction of memory T cell responses to pre-erythrocytic
malaria antigens [42,43]. In a recent RTS,S vaccine challenge
trial, Kester and colleagues demonstrated that the frequency of
CS-specific CD4
+ T cells producing at least 2 immune markers
amongst IL-2, TNF-a, IFN-c and CD40L was significantly higher
in protected subjects as compared to non-protected subjects [3].
Helper T cells promote antibody class switch [44,45], affinity
maturation[46]andinductionofmemoryBcells[47]whichplayan
important role in the induction of high titers of antigen specific IgG
upon secondary exposure. In previous work, a fourth vaccination of
Gambian adults one year after last vaccination with RTS,S/AS02
could significantly boost the anti-CS antibody response, suggesting
that CS-specific memory had been induced [27].
IL-2 produced by antigen-specific CD4
+ T cells may act as a
growth factor for follicular helper T cells [48] and promote the
growth and differentiation of antigen-specific B cells [49].
Follicular helper T cells (TFH) are now recognized as the subset
of helper T cells that regulate the multiple stages of the B cell
compartment [50]. Upon contact with antigen-primed dendritic
cells, TFH migrate to the follicular regions of lymphoid organs to
engage in cell-to-cell contacts with antigen-primed B cells. CD40L,
a marker for activated antigen-specific CD4
+ T cells is a co-
stimulatory molecule which is vital in the delivery of TFH cell help
for the development of antigen-specific memory B cells [51]. It is
unclear why CD40L upregulation was not detected upon antigen
activation. Other experimental approaches may be necessary.
Despite undetectable CD40L expression on circulating CS specific
CD4
+ T cells observed in this study, we found that all children had
detectable and persistent levels of anti-CS serum IgG after
vaccination as well as CS-specific memory B cells up to one year
after last vaccination.
Together, these data show that vaccination with RTS,S/AS01E
and RTS,S/AS02D induces significant CS-specific long term
humoral immunity as well as CS-specific IL-2 producing CD4
+ T
cells in young children. While CD40L was undetectable, the
induction and persistence of CS-specific memory B cells in all
recipient suggest that both RTS,S/AS01E and RTS,S/AS02D
vaccines engaged CD4
+ T helper (TFH) in the development of CS-
specific B cells. These mechanisms may occur with a greater
amplitude following the vaccination with RTS,S/AS01E as it
generated higher frequency of CS-specific memory B cells and
higher level of CS-specific antibodies than RTS,S/AS02D and
could explain the finding that the AS01E adjuvant improved the
RTS,S vaccine efficacy as shown in the sporozoite challenge
model [3]. In addition, CS-specific IL-2
+ CD4
+ T cells are linked
to the memory T cell compartment and may be involved in
RTS,S/AS01E and RTS,S/AS02D vaccine-induced long term
protection. Further immunological investigations in RTS,S
studies, including efficacy studies, will contribute to a better
understanding of vaccine-induced protection against malaria.
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